15 September 2020

Because of the low prevalence, not much is known about the natural history of patients with congenital disorders of glycosylation (CDG). Knowledge about the natural disease course is of major importance to inform patients and parents and to prepare intervention studies. The CDG Biobank contains biomaterial (DNA, plasma (EDTA and heparin) and urine) and specific data from the medical file of participating patients.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl)

19 July 2022

The Ministry of Health, Welfare and Sport (VWS) is currently preparing a Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl) which will serve in the future as a specific legal framework for the (further) use of body tissue for medical scientific research.

read more

Health-RI annual report

19 July 2022

Health-RI has presented the 2021 annual report. In this report they outline an overview of recent activities and results of the past year 2021 (in Dutch).

read more

SPIDI sub-biobank

19 July 2022

The SPIDI collection aims to assess the prognostic value of MRI-DWI (new form of MRI research) and biomarkers (brain-specific proteins in cerebrospinal fluid) in the first 24 hours after the occurrence of a spinal cord injury as a result of trauma.

read more

MyCoS sub-biobank

8 April 2022 The Radboud Biobank has added one new sub-biobank to the collection: MyCoS. read more